Contemporary management of Raynaud's phenomenon and digital ischaemic complications
- 1 November 2011
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Rheumatology
- Vol. 23 (6) , 555-561
Abstract
The present review gives an update of the current management of Raynaud's phenomenon and its ischaemic complications (digital ulceration and critical ischaemia) and discusses possible further developments in the next 5–10 years. New approaches to therapy are being driven by increased understanding of pathophysiology and by increased international networking of clinicians and scientists, facilitating clinical trials. Key points include phosphodiesterase inhibitors most likely confer benefit, although clinical trials have given somewhat conflicting results, and have been short-term; a new topical, easy-to-use glyceryl trinitrate preparation has been shown to improve Raynaud's Condition Score; the endothelin-1 receptor antagonist bosentan has now been shown to reduce the number of new systemic sclerosis (SSc)-related digital ulcers in two multinational clinical trials; and although statin therapy is likely to confer benefit in SSc-related Raynaud's phenomenon, further research is required to confirm this. New therapeutic approaches in patients who do not respond to more traditionally used vasodilators include phosphodiesterase inhibitors and (for those with recurrent SSc-related digital ulcers) endothelin-1 receptor antagonism. Several other potential new therapies are being researched. Optimal management of digital ulceration is multidisciplinary including tissue viability and (sometimes) surgical input.Keywords
This publication has 38 references indexed in Scilit:
- EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)Annals of the Rheumatic Diseases, 2009
- Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based reviewCurrent Opinion in Rheumatology, 2007
- Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: A multicenter, randomized, double‐blind, placebo‐controlled trial of the angiotensin‐converting enzyme inhibitor quinaprilArthritis & Rheumatism, 2007
- Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysisRheumatology, 2004
- Acute and sustained effects of dihydropyridine-type calcium channel antagonists on oxidative stress in systemic sclerosisThe American Journal of Medicine, 2004
- Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetineRheumatology, 2001
- Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosisArthritis & Rheumatism, 2001
- Losartan therapy for Raynaud's phenomenon and scleroderma: Clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trialArthritis & Rheumatism, 1999
- Intravenous Iloprost Infusion in Patients with Raynaud Phenomenon Secondary to Systemic Sclerosis: A Multicenter, Placebo-controlled, Double-Blind StudyAnnals of Internal Medicine, 1994
- Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activationThe American Journal of Medicine, 1985